You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The latest news on microsatellite instability testing.
The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.
The findings should spur cancer centers to review testing rates and address barriers, said experts from Hackensack University, Cota Healthcare, and Guardant Health.
Drugmakers talked about precision oncology acquisitions, and a genetic testing firm discussed the use of artificial intelligence in predicting treatment response.
A new study suggests that colorectal cancers increase their mutation rate to dodge treatment in a manner that mirrors microbial resistance mechanisms.
Promega's microsatellite instability technology will be used to develop an on-label, solid tumor companion diagnostic for pembrolizumab.
LaVallee discussed barriers the field of immuno-oncology faces and the broad landscape of strategies being pursued to overcome them.
The company said it has seen progress in efforts to get FDA approval for its tissue and liquid biopsy tests as data continues to accumulate for pan-cancer utility.
The company is on track to submit Guardant360 to the FDA in the third quarter, but also expects to see pan-cancer reimbursement much sooner.
The latest news on precision oncology research trends.
The actual match rate is significantly higher than the 10 percent rate the researchers anticipated they would see when the study began in 2017.